Autoimmune Uveitis - Market Insights, Epidemiology, and Market Forecast - 2034

Key Highlights:

• The total Autoimmune Uveitis market size in the 7MM was around USD 1,290 million in 2022. This is estimated to increase by 2034 at a significant CAGR.
• In 2022, the Autoimmune Uveitis market size was highest in the US among the 7MM accounting for approximately USD 840 million and lowest in Italy with USD 39 million that is further expected to increase by 2034.
• The majority of Autoimmune Uveitis patients were estimated in the US followed by EU4 and the UK and Japan.
• The distribution of autoimmune uveitis subtypes impacts treatment approaches, prognosis, and resource allocation within healthcare systems. Diagnosed prevalent cases of Autoimmune Uveitis are highest for anterior noninfectious uveitis (aNIU) during the study period, followed by Pan-Uveitis and Posterior Uveitis in the 7MM.
• HUMIRA is the only FDA-approved biologic available in the market. The larger market is covered by Biologics, making up the total Autoimmune Uveitis market of around USD 960 million in 2022, in the 7MM.
• The total market size of the autoimmune uveitis treatment market is anticipated to experience growth during the forecast period due to emerging treatment that includes TRS01, OCS-02, and EYS606.

DelveInsight's "Autoimmune Uveitis Market Insights, Epidemiology and Market Forecast- 2034" report delivers an in-depth understanding of the Autoimmune Uveitis, historical and forecasted epidemiology as well as the Autoimmune Uveitis market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

The Autoimmune Uveitis market report provides current treatment practices, emerging drugs, market share of individual therapies, and current and forecasted 7MM Autoimmune Uveitis market size from 2020 to 2034. The Autoimmune Uveitis market report also covers current Autoimmune Uveitis treatment practices/algorithms and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Autoimmune Uveitis market.

Autoimmune Uveitis Treatment Market

Autoimmune Uveitis Overview

Autoimmune uveitis is an inflammatory process of uveal components due to an autoimmune reaction to self-antigens or is caused by an innate inflammatory reaction secondary to an external stimulus. It can present as an isolated entity or be associated with a systemic autoimmune or auto-inflammatory disease.

In most cases, it affects the uvea but can also impact other parts of the eyes. It is categorized as infectious or noninfectious. Noninfectious Uveitis (NIU) can occur with systemic autoimmune disease and autoimmune diseases localized to the eye. Symptoms of NIU include ocular pain, photophobia, lacrimation, and redness. Common symptoms of uveitis are blurred vision, photophobia, eye pain, floaters (floating spots), headache, and injected conjunctiva; usually, children can be asymptomatic.

Autoimmune uveitis Diagnosis

The management of NIU in adults is challenging and requires precise and early diagnosis to allow prompt therapeutic intervention.

Autoimmune Uveitis Diagnosis begins with a comprehensive symptom review and a thorough exam of both the anterior and posterior segments. A systemic workup is initiated that includes laboratory testing for infectious and noninfectious etiologies, and a chest X-ray is also performed. Once this foundation has been laid, ancillary testing, including optical coherence tomography (OCT) and fluorescein angiography, can provide valuable insight.

The patient journey begins when the patient gets affected by the risk factors such as, infection, surgery, genetic default, and others causing discomfort in the eye. The patient then goes to the general physician, who refer the patient to the ophthalmologist, who then ask the patient to go for diagnostic test such as, slit lamp examination, funduscopic exam, visual acuity test, and ocular pressure test to confirm the disease.

There is no universally accepted approach for the evaluation of uveitis. If the history, physical examination, and basic laboratory tests do not suggest a specific diagnosis, serologic studies for syphilis and chest radiography for sarcoidosis and tuberculosis are recommended.

Autoimmune uveitis Treatment

Treatment for uveitis aims to help relieve pain and discomfort in the eye, underlying cause and reduce inflammation which can prevent permanent loss of vision or other complications. The primary goal of treating uveitis is getting rid of inflammation as fast as possible.

The Standardization of Uveitis Nomenclature Working Group Guidelines recommends using corticosteroids as first-line therapy for patients with active uveitis. Alternatively, immunomodulatory drugs are given as steroid-sparing agents and have shown good clinical results for systemic and ocular inflammatory diseases.

The current treatment market comprises a monoclonal antibody HUMIRA (adalimumab), corticosteroids such as OZURDEX, ILUVIEN, and some off-label therapies.

Autoimmune uveitis Epidemiology

As the Autoimmune Uveitis market is derived using the patient-based model, the Autoimmune uveitis epidemiology chapter in the report provides historical as well as forecasted epidemiology segmented by, Total Diagnosed Prevalent Cases of Uveitis, Type-specific Diagnosed Prevalent Cases of Uveitis, Total Diagnosed Prevalent Cases of NIU by anatomical location, Total Diagnosed Prevalent Cases of Autoimmune Uveitis, and Etiology-specific Diagnosed Prevalent Cases of Autoimmune Uveitis in the 7MM covering the United States, EU4 countries (Germany, France, Italy, and Spain) and the United Kingdom, and Japan from 2020 to 2034. The total diagnosed prevalent cases of Autoimmune Uveitis in the 7MM comprised approximately 0.67 million cases in 2022 and are projected to increase during the forecasted period (2023-2034).

• In 2022, the total diagnosed prevalent cases of uveitis were 0.9 million and for autoimmune uveitis were 0.6 million cases in the 7MM, which is expected to rise by 2034 primarily due to an aging population.
• Uveitis can be noninfectious or infectious. As per our epidemiology model, in 2022, there were 0.1 million cases of infectious uveitis, and 0.7 million cases of non-infectious uveitis in the 7MM.
• The NIU cases were segmented based on their anatomical location as anterior noninfectious uveitis (aNIU), posterior uveitis, intermediate uveitis, and pan-uveitis. The cases of aNIU were highest in the 7MM in 2022 with 0.5 million cases. This may be attributed due to variations in autoimmune mechanisms, environmental triggers, and differing clinical presentations, with aNIU being more easily diagnosed compared to other subtypes.
• In 2022, among the 7MM, the US accounted for the highest number of diagnosed prevalent cases of autoimmune uveitis, i.e. 0.29 million cases which is expected to increase by 2034.
• EU4 and the UK countries accounted for 0.26 million diagnosed prevalent cases of autoimmune uveitis in 2022. In the same year, with 73k cases, Germany accounted for the highest number of diagnosed prevalent cases of autoimmune uveitis in Europe.
• Japan accounted for 17% of the total diagnosed prevalent cases of autoimmune uveitis, i.e. 0.1 million cases in the 7MM in 2022.

Autoimmune uveitis Drug Chapters

The Autoimmune Uveitis drug chapter segment of the autoimmune uveitis market report encloses a detailed analysis of autoimmune uveitis marketed drugs and late-stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the autoimmune uveitis clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Marketed Autoimmune Uveitis Drugs

YUTIQ: Eyepoint Pharmaceuticals

YUTIQ is a sterile nonbioerodible intravitreal implant with 0.18 mg FA (fluocinolone acetonide). It releases the drug at an initial rate of 0.25 μg/day in a 36-month sustained-release drug delivery system. YUTIQ was designed to improve the performance of RETISERT to deliver a lower dose of corticosteroid to the retina with fewer adverse events.

EyePoint is also developing a next-generation, shorter-duration treatment for chronic noninfectious uveitis affecting the posterior segment of the eye, based on the Durasert technology. This insert is designed to offer a shorter delivery period, thus providing physicians with flexibility for multiple dosing intervals.

HUMIRA (Adalimumab): AbbVie Inc.

HUMIRA is the commercially available preparation of adalimumab being developed by AbbVie Inc. for treating noninfectious intermediate, posterior, and panuveitis; it acts by binding to the tumor necrosis factor (TNF) alpha.

It limits the autoimmune response by preventing the induction of inflammatory cytokines, thus limiting autoimmune response

Emerging Autoimmune Uveitis Drugs

TRS01: Tarsier Pharma

TRS01 is a polypeptide conjugate with a dual mechanism of action; the investigational agent induces anti-inflammatory macrophages and inhibits the nuclear factor-kB (Nf-kB) signaling pathway by toll-like receptor 4 (TLR4). TRS is a proprietary, bio-inspired platform for treating blinding ocular diseases.

The positive findings of this TRS01 clinical trial point to significant advancements in developing a new class of clinically significant ocular therapeutics, with efficacy at least comparable to corticosteroids, with lesser to no side effects. Hence, it might have the potential to outperform other corticosteroids in the noninfectious uveitis treatment market.

OCS-02: Oculis Pharma

Licaminlimab (OCS-02) is a single-chain antibody fragment (scFv) that binds to and neutralizes the activity of human TNFa, with a dual mechanism of action (MoA), anti-inflammation, and anti-necrosis.

If approved OCS-02 is anticipated as first topical, nonsteroidal therapy or biologic for noninfectious anterior uveitis.

Autoimmune uveitis Market Outlook

Treating NIU and other autoimmune-mediated diseases is rarely as simple as blocking a single molecule and turning a single switch on or off. Still, in recent years, targeted biologic treatments such as HUMIRA for the autoimmune disease have been approved, including some specifically for NIU.

Local treatments for NIU largely include corticosteroids, though intraocular injection of agents such as sirolimus and methotrexate have been studied. Currently approved options for local therapy include topical steroids, shorter-acting intra-and periocular steroids, such as triamcinolone acetonide, and sustained-release intravitreal implants, including OZURDEX and YUTIQ.

The launch of emerging Autoimmune Uveitis therapies, such as TRS01 eye drops (for noninfectious anterior uveitis), OCS-02 (acute anterior uveitis), and EYS606: Combination product (chronic noninfectious uveitis), and others are expected to create a positive impact on the Autoimmune Uveitis market.

• The total Autoimmune Uveitis market size in the 7MM was around USD 1,290 million in 2022. This is estimated to increase by 2034 at a significant CAGR.
• Among the 7MM, the US consistently captured the highest Autoimmune Uveitis market of around USD 840 million in 2022, which is anticipated to grow during the forecast period (2023-2034).
• In 2022, EU4 and the UK countries captured an estimated USD 312 million, and Japan covered Autoimmune Uveitis market of about USD 137 million.
• Biologics are expected to capture highest Autoimmune Uveitis market in the 7MM by 2034.

Autoimmune uveitis Drugs Uptake

This section focuses on the rate of uptake of the potential Autoimmune Uveitis drugs expected to get launched in the Autoimmune Uveitis market during the study period 2020-2034. For example, for TRS01 eye drops, we expect the drug uptake to be medium with a probability-adjusted peak share of around 10%, and years to the peak is expected to be 7 years from the year of launch.

Autoimmune uveitis Pipeline Development Activities

The Autoimmune Uveitis market report provides insights into different therapeutic candidates in Phase III, Phase II, and Phase I stage. It also analyzes key players involved in developing targeted therapeutics.

Pipeline Development Activities

The Autoimmune Uveitis market report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for Autoimmune Uveitis emerging therapies.

Autoimmune Uveitis KOL- Views

To keep up with current Autoimmune Uveitis market trends, we take KOLs and SMEs' opinions working in the domain through primary research to fill the data gaps and validate our secondary research. Industry Experts contacted for insights on Autoimmune Uveitis evolving treatment landscape, patient reliance on conventional therapies, patient's therapy switching acceptability, and drug uptake along with challenges related to accessibility, include KOL from University of Nebraska Medical Center Omaha, Nebraska, US; University Hospital Heidelberg, Germany; Universite Pierre et Marie Curie, Paris, France; University of Liverpool, Neston, UK; Department of Innovative Visual Science, Osaka University, Japan; and Others.

Delveinsight's analysts connected with 50+ KOLs to gather insights, however, interviews were conducted with 15+ KOLs in the 7MM. Their opinion helps to understand and validate current and emerging therapies and treatment patterns or Autoimmune Uveitis market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the Autoimmune Uveitis market and the unmet needs.

Qualitative Analysis

We perform Qualitative and market Intelligence analysis using various approaches, such as SWOT analysis, and Conjoint Analysis. In the SWOT analysis, strengths, weaknesses, opportunities, and threats in terms of disease diagnosis, patient awareness, patient burden, competitive landscape, cost-effectiveness, and geographical accessibility of therapies are provided. These pointers are based on the Analyst's discretion and assessment of the patient burden, cost analysis, and existing and evolving treatment landscape.

Conjoint Analysis is done to analyze multiple approved and emerging therapies based on relevant attributes such as safety, efficacy, frequency of administration, route of administration, and order of entry. Scoring is given based on these parameters to analyze the effectiveness of therapy.

Further, the therapies' safety is evaluated wherein the acceptability, tolerability, and adverse events are majorly observed, and it sets a clear understanding of the side effects posed by the drug in the trials. In addition, the scoring is also based on the route of administration, order of entry and designation, probability of success, and the addressable patient pool for each therapy. According to these parameters, the final weightage score and the ranking of the emerging therapies are decided.

Autoimmune Uveitis Market Access and Reimbursement

Reimbursement is a crucial point for any drug after its approval. The YUTIQ developing company EyePoint Pharmaceuticals, Inc. provides EyePoint Assist HCP Portal that allows patients for a benefits investigation, confirm insurance eligibility, and gain access to financial and reimbursement support.

The Autoimmune Uveitis market report further provides detailed insights on the country-wise accessibility and reimbursement scenarios, cost-effectiveness scenario of approved therapies, programs making accessibility easier and out-of-pocket costs more affordable, insights on patients insured under federal or state government prescription drug programs, etc.

Scope of the Autoimmune Uveitis Market Report

• The Autoimmune Uveitis market report covers a segment of key events, an executive summary, descriptive overview of Autoimmune uveitis, explaining its causes, signs and symptoms, pathogenesis, and currently available therapies
• Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of diagnosis rate, disease progression along with treatment guidelines
• Additionally, an all-inclusive account of both the current and emerging therapies along with the elaborative profiles of late-stage and prominent therapies will have an impact on the current treatment landscape
• A detailed review of the Autoimmune uveitis market; historical and forecasted market size, market share by therapies, detailed assumptions, and rationale behind our approach is included in the report, covering the 7MM drug outreach
• The Autoimmune Uveitis market report provides an edge while developing business strategies, by understanding trends, through SWOT analysis and expert insights/KOL views, patient journey, and treatment preference that help in shaping and driving the 7MM Autoimmune uveitis market

Autoimmune Uveitis Market Report Insights

• Autoimmune uveitis Patient Population
• Autoimmune uveitis Therapeutic Approaches
• Autoimmune uveitis Pipeline Analysis
• Autoimmune uveitis Market Size
• Autoimmune Uveitis Market Trends
• Existing and future Market Opportunity

Autoimmune Uveitis Market Report Key Strengths

• Twelve Years Forecast
• 7MM Coverage
• Autoimmune uveitis Epidemiology Segmentation
• Key Cross Competition
• Conjoint analysis
• Autoimmune Uveitis Drugs Uptake
• Key Autoimmune Uveitis Market Forecast Assumptions

Autoimmune Uveitis Market Report Assessment

• Current Autoimmune uveitis Treatment Practices
• Autoimmune uveitis Unmet Needs
• Autoimmune uveitis Pipeline Product Profiles
• Autoimmune uveitis Market Attractiveness
• Qualitative Analysis (SWOT and Conjoint Analysis)
• Autoimmune uveitis Market Drivers
• Autoimmune uveitis Market Barriers

Key Questions Answered In The Autoimmune Uveitis Market Report:

Autoimmune Uveitis Market Insights:

• What was the autoimmune uveitis market size, the market size by therapies, and market share (%) distribution in 2020, and how it would all look in 2034? What are the contributing factors for this growth?
• What are the unmet needs are associated with the current treatment market of autoimmune uveitis?
• What will be the impact of YUTIQ's expected patent expiry by 2027?
• How is TRS01 going to compete with the existing therapies for autoimmune uveitis after approval?
• Which drug is going to be the largest contributor in 2034?
• What are the pricing variations among different geographies for approved and off-label Autoimmune Uveitis therapies?
• How would the market drivers, barriers, and future opportunities affect the Autoimmune Uveitis market dynamics and subsequent analysis of the associated trends?

Autoimmune Uveitis Epidemiology Insights:

• What are the disease risk, burden, and unmet needs of autoimmune uveitis? What will be the growth opportunities across the 7MM concerning the patient population of autoimmune uveitis?
• What is the historical and forecasted Autoimmune uveitis patient pool in the United States, EU4 (Germany, France, Italy, and Spain) the United Kingdom, and Japan?
• Why do only limited patients appear for diagnosis? Why is the current year diagnosis rate not high?
• Which severity stage is more prevalent and why?
• What factors are affecting the diagnosis of the indication?

Current Autoimmune Uveitis Treatment Scenario, Marketed Drugs, and Emerging Therapies:

• What are the current options for the treatment of autoimmune uveitis? What are the current treatment guidelines for the treatment of Autoimmune uveitis in the US and Europe?
• How many Autoimmune Uveitis companies are developing therapies for the treatment of autoimmune uveitis?
• How many emerging Autoimmune Uveitis therapies are in the mid-stage and late stage of development for the treatment of autoimmune uveitis?
• What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
• What are the key designations that have been granted for the emerging therapies for autoimmune uveitis?
• What will be the impact of YUTIQ's expected patent expiry?
• What is the cost burden of approved therapies on the patient?
• Patient acceptability in terms of preferred treatment options as per real-world scenarios?
• What are the country-specific accessibility issues of expensive, recently approved therapies? Focus on reimbursement policies.
• What are the 7MM historical and forecasted Autoimmune Uveitis market?

Reasons to buy Autoimmune Uveitis Market Report

• The Autoimmune Uveitis market report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the Autoimmune uveitis Market
• Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing Autoimmune Uveitis market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of approved products in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming Autoimmune Uveitis companies in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the Conjoint analysis section to provide visibility around leading classes
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs
• To understand the perspective of Key Opinion Leaders' around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in future
• Detailed insights on the unmet need of the existing market so that the upcoming Autoimmune Uveitis companies can strengthen their development and launch strategy